⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVCT News
Nuvectis Pharma, Inc. Common Stock
Form 8-K
sec.gov
NVCT
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
globenewswire.com
NVCT
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
globenewswire.com
NVCT
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
globenewswire.com
NVCT
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
globenewswire.com
NVCT
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
globenewswire.com
NVCT
Nuvectis Pharma To Participate in Upcoming Investor Conferences
globenewswire.com
NVCT
Form 8-K
sec.gov
NVCT
Form 8-K
sec.gov
NVCT
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
globenewswire.com
NVCT